Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics
OVER YOUR SHOULDER, YOU MAY HEAR THE CLOCK TICKING when it comes to laboratory test reimbursement rate cuts coming under the Protecting Access to Medicare Act of 2014 (PAMA). Short of action by Congress, on Jan. 1, 2026, more than 800 tests will get hit with up to a 15% reduction in rates. It’s a […]
RESULTS Act Offers Another Chance at PAMA Relief Read More »
THERE ARE MANY WAYS TO VIEW CLINICAL LABORATORY OUTREACH ACQUISITIONS and the enormous amount of money changing hands in these deals. From one point of view, those fearful of the continued expansion of national lab giants like Labcorp and Quest Diagnostics may shiver every time one of these companies grabs a new outreach site. Meanwhile,
An Insider’s Observances of Lab Outreach Deals Read More »
PROBABLY SINCE THE ADVENT OF MANAGED CARE, CLAIMS REIMBURSEMENT at its core has been about data. And lots of it. True, it was reams of paper about claims at one point, and now it’s largely digital submissions. The format is irrelevant; those claims contain useful strategic information for both payers and clinical laboratories. Of course,
Don’t Let the Payers Enjoy All the Benefits of Data Read More »
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Perhaps you saw news coverage recently when the US military dropped a dozen or so “bunker buster” bombs into underground Iranian nuclear facilities. I hawkishly contend that diagnostic lab directors and anatomical
National Enforcement Trends Will Test Labs Read More »
READING THROUGH THE FIRST INSTALLMENT OF THE DARK REPORT’S analysis about the state of artificial intelligence (AI) in clinical laboratories, this cantankerous observer found himself thinking about ChatGPT. Do I dare to use ChatGPT? Occasionally. Am I fluent in how to craft meaningful queries using Chat? No. Do I need to improve my game with
For Lab Veterans, It’s Time to Step into AI’s Shadow Read More »
ONE NEED NOT LOOK FURTHER THAN THE PAGES OF THIS ISSUE OF THE DARK REPORT to once again realize the importance of the diagnostic data residing within your clinical laboratory operations. Perhaps it’s rote to say “diagnostic data is a gold mine” for labs. But if all labs truly acted on that notion, wouldn’t everyone
Others Want Diagnostic Data, Labs Should Too Read More »
CLINICAL LABORATORY PROFESSIONALS HAVE RECEIVED A RARE CHANCE for their unified efforts to make a long-term difference in the regulation of the industry. Of course, that endeavor won’t come easy. As detailed in the pages of this issue, two high-priority concerns are awaiting a firm hand of guidance from conscientious labs: The future of laboratory
Don’t Pass Up Chance to Steer LDTs, PAMA Reform Read More »
VICTORY IN COURT! FOR AN INDUSTRY THAT OFTEN FINDS ITSELF on the wrong end of legal deliberations (see Theranos or various Department of Justice cases), it feels good to have a judge side with clinical laboratories. We are, of course, talking about the recent ruling from Judge Sean Jordan in Texas in which he
Enjoy the LDT Court Victory, Yet Remain Vigilant Read More »
We already see the second term of President Donald Trump influencing clinical laboratory business operations. It’s not The Dark Report’s stance to jump on the political soapbox of whether Trump’s actions are a tragedy or a boon; let the cable TV pundits debate that. However, as with any move—business, political, or otherwise—the success or failure
White House Is Off to a Fast Start, So Pay Attention Read More »
TODAY, IT’S A CHALLENGE TO STAY UP WITH ALL THE NEW THINGS arriving in the lab testing marketplace. Novel assays are launched weekly. That is equally true for next-generation automation and lab analyzers, with vendors regularly announcing something new to their menu of products. The pace of innovation involving information technology is moving even faster.
Innovations in Lab Testing Arriving at Light Speed Read More »